Autopsy report · NCT02243189

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

“Under enrollment and IP supply expiring.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 months before it stopped.
• 17 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Janssen Research & Development, LLC

Sponsor type

Industry

Conditions

Healthy; Asthma

Interventions

JNJ-43260295; Placebo; Nasal Allergen Challenge

Participants

17

Sites

1

Countries

United States

Trials that died the same way

• A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
  “Due to company's assessment of enrollment feasibility.” (59% match in meaning)
• Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma
  “discontinued due to low enrollment” (56% match in meaning)
• Proton Radiation Therapy for Pituitary Adenoma
  “Due to slow enrollment and feasibility issues.” (56% match in meaning)
• Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
  “pending expiration of the supply of study agent.” (55% match in meaning)
• Dopamine Rhythms in Health and Addiction
  “No enrollment, delay with drug availability.” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.